These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22092292)

  • 1. Applying the PRECIS criteria to describe three effectiveness trials of weight loss in obese patients with comorbid conditions.
    Glasgow RE; Gaglio B; Bennett G; Jerome GJ; Yeh HC; Sarwer DB; Appel L; Colditz G; Wadden TA; Wells B
    Health Serv Res; 2012 Jun; 47(3 Pt 1):1051-67. PubMed ID: 22092292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of PRECIS ratings in the National Institutes of Health (NIH) Health Care Systems Research Collaboratory.
    Johnson KE; Neta G; Dember LM; Coronado GD; Suls J; Chambers DA; Rundell S; Smith DH; Liu B; Taplin S; Stoney CM; Farrell MM; Glasgow RE
    Trials; 2016 Jan; 17():32. PubMed ID: 26772801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating pragmatic and implementation science randomized clinical trial approaches: a PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) analysis.
    Zatzick D; Palinkas L; Chambers DA; Whiteside L; Moloney K; Engstrom A; Prater L; Russo J; Wang J; Abu K; Iles-Shih M; Bulger E
    Trials; 2023 Apr; 24(1):288. PubMed ID: 37085877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do randomized controlled nursing trials have a pragmatic or explanatory attitude? Findings from the Pragmatic-Explanatory Continuum Indicator Summary (PRECIS) tool exercise.
    Palese A; Bevilacqua MG; Dante A;
    J Nurs Res; 2014 Sep; 22(3):216-20. PubMed ID: 25111115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How pragmatic is it? Lessons learned using PRECIS and RE-AIM for determining pragmatic characteristics of research.
    Gaglio B; Phillips SM; Heurtin-Roberts S; Sanchez MA; Glasgow RE
    Implement Sci; 2014 Aug; 9():96. PubMed ID: 25163664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PRECIS-2 tool has good interrater reliability and modest discriminant validity.
    Loudon K; Zwarenstein M; Sullivan FM; Donnan PT; Gágyor I; Hobbelen HJSM; Althabe F; Krishnan JA; Treweek S
    J Clin Epidemiol; 2017 Aug; 88():113-121. PubMed ID: 28603007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Making clinical trials more relevant: improving and validating the PRECIS tool for matching trial design decisions to trial purpose.
    Loudon K; Zwarenstein M; Sullivan F; Donnan P; Treweek S
    Trials; 2013 Apr; 14():115. PubMed ID: 23782862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How pragmatic or explanatory is the randomized, controlled trial? The application and enhancement of the PRECIS tool to the evaluation of a smoking cessation trial.
    Selby P; Brosky G; Oh PI; Raymond V; Ranger S
    BMC Med Res Methodol; 2012 Jul; 12():101. PubMed ID: 22824225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework.
    Sharma T; Qamar I; Zwarenstein M
    J Clin Epidemiol; 2022 Dec; 152():193-200. PubMed ID: 36265553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains.
    Lipman PD; Loudon K; Dluzak L; Moloney R; Messner D; Stoney CM
    Trials; 2017 Nov; 18(1):532. PubMed ID: 29126437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dynamic application of PRECIS-2 to evaluate implementation in a pragmatic, cluster randomized clinical trial in two nursing home systems.
    Palmer JA; Mor V; Volandes AE; McCreedy E; Loomer L; Carter P; Dvorchak F; Mitchell SL
    Trials; 2018 Aug; 19(1):453. PubMed ID: 30134976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progress in research of pragmatic-explanatory continuum indicator summary].
    Hu G; Hu Y; Zhan S
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Mar; 37(3):439-42. PubMed ID: 27005554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The PRECIS-2 tool: designing trials that are fit for purpose].
    Hu GP; Zhan SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Feb; 39(2):222-226. PubMed ID: 29495210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of pragmatism in explaining heterogeneity in meta-analyses of randomised trials: a protocol for a cross-sectional methodological review.
    Aves T; Allan KS; Lawson D; Nieuwlaat R; Beyene J; Mbuagbaw L
    BMJ Open; 2017 Sep; 7(9):e017887. PubMed ID: 28871028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inter-rater Reliability Assessment of ASPECT-R: (A Study Pragmatic-Explanatory Characterization Tool-Rating).
    Bossie CA; Alphs LD; Williamson D; Mao L; Kurut C;
    Innov Clin Neurosci; 2016; 13(3-4):27-31. PubMed ID: 27354926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHARTing a Path to Pragmatic Tobacco Treatment Research.
    Cruvinel E; Richter KP; Stoney C; Duffy S; Fellows J; Harrington KF; Rigotti NA; Sherman S; Tindle HA; Shireman TI; Shelley D; Waiwaiole L; Cummins S
    Am J Prev Med; 2016 Oct; 51(4):630-6. PubMed ID: 27647063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative Oncology Trials in the Real World: Assessing the Pragmatism of an Ongoing Integrative Oncology Trial of Mindfulness and T'ai Chi/Qigong.
    Carlson LE; Oberoi DV; Qureshi M; Subnis U
    J Altern Complement Med; 2018; 24(9-10):926-932. PubMed ID: 30247962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of meta-analytic methods for synthesizing evidence from explanatory and pragmatic trials.
    Sajobi TT; Li G; Awosoga O; Wang M; Menon BK; Hill MD; Thabane L
    Syst Rev; 2018 Jan; 7(1):19. PubMed ID: 29370830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of the pragmatic-explanatory continuum indicator summary wheel in an ongoing study: the bullous pemphigoid steroids and tetracyclines study.
    Bratton DJ; Nunn AJ; Wojnarowska F; Kirtschig G; Sandell A; Williams HC
    Trials; 2012 Apr; 13():50. PubMed ID: 22540678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.